In last trading session, ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) saw 0.24 million shares changing hands with its beta currently measuring 0.22. Company’s recent per share price level of $0.40 trading at -$0.01 or -2.08% at ring of the bell on the day assigns it a market valuation of $11.15M. That closing price of IPA’s stock is at a discount of -550.0% from its 52-week high price of $2.60 and is indicating a premium of 20.0% from its 52-week low price of $0.32. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 520.96K if we extend that period to 3-months.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
Upright in the red during last session for losing -2.08%, in the last five days IPA remained trading in the green while hitting it’s week-highest on Tuesday, 11/26/24 when the stock touched $0.40 price level, adding 3.61% to its value on the day. ImmunoPrecise Antibodies Ltd’s shares saw a change of -76.64% in year-to-date performance and have moved 3.52% in past 5-day. ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) showed a performance of -26.22% in past 30-days. Number of shares sold short was 0.69 million shares which calculate 0.7 days to cover the short interests.
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
Statistics highlight that ImmunoPrecise Antibodies Ltd is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -63.68% of value to its shares in past 6 months, showing an annual growth rate of 61.54% while that of industry is 24.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 3.30% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.44M for the same. And 2 analysts are in estimates of company making revenue of 6.71M in the next quarter. Company posted 6.15M and 6.22M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.23% during past 5 years.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
Insiders are in possession of 12.06% of company’s total shares while institution are holding 6.58 percent of that, with stock having share float percentage of 7.48%. Investors also watch the number of corporate investors in a company very closely, which is 6.58% institutions for ImmunoPrecise Antibodies Ltd that are currently holding shares of the company. INGALLS & SNYDER LLC is the top institutional holder at IPA for having 1.3 million shares of worth $1.31 million. And as of 2024-06-30, it was holding 5.0209 of the company’s outstanding shares.
The second largest institutional holder is RENAISSANCE TECHNOLOGIES LLC, which was holding about 63910.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.2477 of outstanding shares, having a total worth of $64549.0.
